Dimensional Fund Advisors
GLUE icon

Dimensional Fund Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Dimensional Fund Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.1M Buy
1,041,372
+473,005
+83% +$9.05M ﹤0.01% 2041
2025
Q4 		$8.91M Sell
568,367
-63,815
-10% -$860K ﹤0.01% 2321
2025
Q3 		$4.68M Buy
632,182
+184,020
+41% +$975K ﹤0.01% 2562
2025
Q2 		$2.02M Buy
448,162
+185,172
+70% +$826K ﹤0.01% 2756
2025
Q1 		$1.22M Buy
262,990
+118,179
+82% +$725K ﹤0.01% 2841
2024
Q4 		$1M Buy
144,811
+5,538
+4% +$41.6K ﹤0.01% 2914
2024
Q3 		$738K Sell
139,273
-14,485
-9% -$73.1K ﹤0.01% 2961
2024
Q2 		$575K Buy
153,758
+81,083
+112% +$413K ﹤0.01% 3006
2024
Q1 		$512K Buy
72,675
+48,362
+199% +$287K ﹤0.01% 3038
2023
Q4 		$137K Sell
24,313
-12,971
-35% -$50.9K ﹤0.01% 3245
2023
Q3 		$179K Buy
37,284
+16
+0% +$103 ﹤0.01% 3231
2023
Q2 		$255K Hold
37,268
– – ﹤0.01% 3196
2023
Q1 		$290K Buy
+37,268
New +$259K ﹤0.01% 3128

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Dimensional Fund Advisors's GLUE Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 83% in Q1 2026, buying an estimated $9.05M and bringing the position to 1,041,372 shares worth $17.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

Dimensional Fund Advisors first reported a position in GLUE in Q1 2023 and has held it in 13 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Dimensional Fund Advisors held 1,041,372 shares of Monte Rosa Therapeutics worth $17.1M as of Q1 2026.
  • Dimensional Fund Advisors bought 473,005 Monte Rosa Therapeutics shares in Q1 2026, an estimated $9.05M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2041 holding.
  • Dimensional Fund Advisors first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.